Prevalence and antifungal susceptibility of vulvovaginal candidiasis in women living in Luanda
Keywords:
Candidiasis, Fungal infection, AngolaAbstract
Introduction: vulvovaginal candidiasis is one of the most common problems in women's health. Objective: to describe the prevalence and antifungal sensitivity of vulvovaginal candidiasis in women living in Luanda province from January to June 2021. Methods: a cross-sectional descriptive study was conducted. The universe was constituted by 404 women with diagnosis of vaginitis, referred to the laboratory of the National Institute of Health Research of Angola. A sample of vaginal secretion was collected for direct examination and culture. The VITEK® 2 chart was used to identify Candida species and the sensitivity profile of these fungi to antifungals. Results: the average age of the patients was 33 years. The prevalence of vulvovaginal candidiasis was 31.4%. Candida albicans was detected in 95.3% of patients. 98% of Candida-positive women presented symptoms associated with Candida infection, with a predominance of pruritus in 38.3% of patients, followed by vaginal secretions (36.7%) and dyspareunia (18%). Candida albicans showed 100% sensitivity to nystatin antifungals. The remaining Candida species were sensitive to all antifungal agents. Conclusions: the high prevalence of Candida albicans in the investigated women represents a challenge for the well-being of Angolan women. It is necessary to work on early diagnosis through periodic screening for vulvovaginal candidiasis with antifungal sensitivity tests to help prevent future complications in women.
Downloads
References
2. Vieira-Baptista P, AR Silva, Costa M, Aguiar T, Saldanha C, Sousa C. Clinical validation of a new molecular test (Seegene Allplex™ Vaginitis) for the diagnosis of vaginitis: a cross-sectional study. First published [Internet]. 2021 [citado: 10/1/2024]. Disponible en: https://doi.org/10.1111/1471-0528.16661
3. Sacato E. Etiología de las infecciones fúngicas vaginales en la región de Lubango-Huila y resistencia a los antifúngicos. [Tesis para la obtención del título de Magíster en Ciencias Biomédicas, especialidad de Biología Molecular] Lisboa: Nueva Universidad de Lisboa. Instituto de Higiene y Medicina Tropical; 2013.
4. Story K, Sobel R. Profilaxis con fluconazol en la prevención de la vaginitis por Cándida sintomática. Curr Infect Dis Rep [Internet]. 2020 [citado: 23/1/2023];22(1):2. Disponible en: https://doi.org/10.1007/s11908-020-0712-7
5. Sobel J, Mitchell C. Candida vulvovaginitis: clinical manifestations and diagnosis. Up to date. 2022;1:22.
6. González F, Gutiérrez H, Méndez M. Candidiasis vulvovaginal recurrente. Revista Médica Sinergia .2021;6(9):e700
7. Balakrishnan S, Yamang H, Lorenz M, Chew S, Lung L. Role of vaginal mucosa, host immunity and Microbiota in Vulvovaginal candidiasis. Pathogens. 2022; 11(618): 1- 15.
8. OPS. Cándida auris, un patógeno emergente. Acciones y prevención en Colombia [InterneT]. 2021 [CITADO: 23/1/2023]. Disponible en: https://www.paho.org/es/noticias/10-3-2021-candida-auris-patogeno-emergente-acciones-prevencion-colombia
9. Herreras-Gómez LR, López-Cárdenas V. Perfil de resistencia antifúngica en el tratamiento de candidiasis vaginal: Un diagnóstico de agentes etiológicos. Rev haban cienc méd [Internet]. 2022 [citado: 8/2/2023];21(2): e4241. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729519X2022000200011&lng=es
10. Sanches JM, Giraldo PC, Bardin MG, Amaral R, Discacciati MG, Rossato L .Laboratorial Aspects of Cytolytic Vaginosis and Vulvovaginal Candidiasis as a Key for Accurate Diagnosis: A Pilot Study. Rev Bras Ginecol Obstet [Internet]. 2020 [citado: 8/2/2023];42(10):635–642. DOI: doi.org/10.1055/s-0040-1715139
11. Rensi Botelho TK, Jacobi Danielli L , Seide M , Pacassa Borges P , Bella Cruz A. Distribution and antifungal susceptibility of Candida species isolated from clinical samples in southern Brazil. Braz. J. Pharm. Sci. [Internet]. 2022 [citado: 8/2/2023];58: e20727. DOI: doi.org/10.1590/s2175-97902022e20727
12. Revankar SD. Candidiasis (invasora). Manual MSD. Versión para profesionales. Revisado/Modificado [Internet]. 2021 [citado: 8/2/2024]; Disponible en: https://www.msdmanuals.com/es-ec/professional/enfermedades-infecciosas/hongos/fámacos antimicóticos
13. Salud OPdl. Organización Panamericana de la Salud [Internet]. 2021 [citado: 20/9/2022]. Disponible en: https://www.paho.org/es/noticias/10-3-2021
14. Patel MA, Aliporewala VM, Patel DA. Common Antifungal Drugs in Pregnancy: Risks and Precautions. J Obstet Gynaecol India. 2021 Dec;71(6):577-582.
15. Spengler-González L, Ayala-Rodríguez I, García-Rodríguez A. Infecciones cervicovaginales en exudados vaginales. Rev Cub Med Mil [Internet]. 2020 [citado 20/4/2024];49(3): e578. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-65572020000300008&lng=es
16. SALUD OMD. Organización Mundial de Salud. [Internet]. 2022 [citado: 23/4/2022]. Disponible en: https://www.who.int/es.8
17. Jaqueti-Aroca J, Ramiro-Martínez P, Molina-Esteban LM, Fernández-González AM, García-Arata I, Prieto-Menchero S. Epidemiología y etiología de la candidiasis vaginal en mujeres españolas e inmigrantes en Fuenlabrada (Madrid). Rev Esp Quimioter. 2020; 33(3): 187–192.
18. Guía de Asistencia Práctica. Diagnóstico y tratamiento de las infecciones vulvovaginales. Prog Obstet Ginecol. 2022; 65:61-75.
19. Calvo Jiménez J, González Garro AR, Triunfo Trabado SJ. Generalidades de la candidiasis vulvovaginal. Rev Méd Sin [Internet]. 2023 [citado 8/2/2024]; 8(3): 924. https://doi.org/10.31434/rms.v8i3.924
20. Sánchez-Tapia MA, González-Armijos VY. Infecciones vaginales y complicaciones durante el embarazo en usuarias del Centro de Salud Universitario de Motupe – Loja. CEDAMAZ [Internet]. 2021 [citado 8/2/2024];11(2):119–123. DOI: https://doi.org/10.54753/cedamaz.v11i2.11
21. Grigol-Bardin M, Giraldo PC, Benetti-Pinto CL, Sanches JM, Carvalho-de Araujo C, Gomes-do Amaral RL. Hábitos de higiene genital e atividade sexual entre mulheres com vaginose bacteriana e/ou candidíase vulvovaginal. Rev Bras Ginecol Obstet [Internet]. 2022 [citado 8/2/2024];44(2):169–177. DOI: https://doi.org/10.1055/s-0041-1741536
22. Moina-Rivera EM. Diagnóstico de laboratorio para Cándida Albicans en mujeres sexualmente activas Tesis Laboratorio Clinico e Histopatológico. Repositorio Digital UNACH. [Internet]. 2021 [citado: 8/2/2024].Disponible en http://dspace.unach.edu.ec/handle/51000/7247
23. Llanes RM, González RO, Sánchez ML, et al. Prevalencia de Trichomonas vaginalis, Candida albicans y Gardnerella vaginalis en mujeres sin síntomas de vaginitis. Revista Habanera de Ciencias Médicas. 2014; 20(2):164-174.
24. Salud OPdl. OPS. [Online]. 2021 [citado: 8/2/2024] Available from: https://www.paho.org/es/noticias/10-3-2021-candida-auris-patogeno-emergente-accionesprevencion-colombia
25. Alcaciega AD, Recalde-Navarrete R. Vulvovaginitis candidiásica en el embarazo: enfoque diagnóstico, tratamiento actual y complicaciones: Artículo de Revisión. Ciencia Ecuador [Internet]. 2022 [citado 8/2/2024];4(4):1-11. Disponible en: https://cienciaecuador.com.ec/index.php/ojs/article/view/101
26. Yassin MT, Mostafa AA, Al-Askar AA, Bdeer R. Perfil de resistencia antifúngica in vitro de cepas de Cándida aisladas de mujeres sauditas que padecen vulvovaginitis. Eur J Med Res. 4 de enero de 2020; 25(1):1.
27. Dueñas P, Muñoz-de la Torre RJ. Candidiasis Vulvovaginal y Susceptibilidad Antifúngica en Gestantes de la Sierra Andina – Huancavelica. Ciencia Latina Revista Científica Multidisciplinar [Internet]. 2023 [citado 8/2/2024];7(5). DOI: https://doi.org/10.37811/cl_rcm.v7i5.8332
28. Willems HME, Ahmed SS, Liu J, Xu Z, and Peters BM. Vulvovaginal Candidiasis: A Current Understanding and Burning Questions. J Fungi (Basel). 2020;6(1):27.
Published
How to Cite
Issue
Section
License
Those authors who have publications with this journal accept the following terms:
The authors will retain their copyright and guarantee the journal the right of first publication of their work, which will be under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) that allows the use of the work to share (copy and redistribute the material in any medium or format) and adapt (remix, transform and build on the material) as long as mention is made of the publication in the journal as the primary source. However, you will not be able to trade with it.
The authors may adopt other non-exclusive license agreements for the distribution of the version of the published work (eg: deposit it in an institutional telematic file or preprint servers) provided that the initial publication in this journal is indicated.
The Cuban Health Technology Magazine is authorized by a Creative Commons Attribution-NonCommercial 4.0 International License.
